Cerenome, Inc. (CNSY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cerenome, Inc. (CNSY) has a cash flow conversion efficiency ratio of -1.306x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($5.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Cerenome, Inc. for the company's overall valuation and market capitalisation.
Cerenome, Inc. - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Cerenome, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Cerenome, Inc. stock price today for real-time trading data and today's change.
Cerenome, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerenome, Inc. ranked by their cash flow conversion efficiency. Review free cash flow generation of Cerenome, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jupiter Energy Ltd
AU:JPR
|
-2.651x |
|
Kordsa Global Endustriyel Iplik ve Kord Bezi Sanayi ve Ticaret AS
IS:KORDS
|
0.077x |
|
Lagnam Spintex Limited
NSE:LAGNAM
|
0.366x |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
|
Pegasus Heights Bhd
KLSE:4464
|
0.018x |
|
Sungchang Autotech Co. Ltd
KQ:080470
|
-0.086x |
|
CNFinance Holdings Ltd
NYSE:CNF
|
-0.012x |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
3.473x |
Annual Cash Flow Conversion Efficiency for Cerenome, Inc. (1998–2025)
The table below shows the annual cash flow conversion efficiency of Cerenome, Inc. from 1998 to 2025. Also see Cerenome, Inc. (CNSY) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -133.43% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more